Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer

M. Giai, R. Roagna, R. Ponzone, M. De Bortoli, C. Dati, P. Sismondi

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The protein product of c-erbB-2 and ras oncogene has been examined for its prognostic potential in both node positive and node negative breast cancer. Using a western blot analysis, levels of these proteins were determined in 159 primary human breast tumor specimens. We examined relationships between gene expression and coexpression with other established markers of prognosis, as well as clinical outcome. Multivariate analysis showed that nodal involvement was the most powerful prognostic factor for predicting overall survival (<0.000) and disease-free survival (p = 0.001), whereas c-erbB-2 expression was second only to nodal status for predicting overall survival in the whole series (p = 0.05). A separated stepwise analysis was conducted for node negative patients who did not receive any kind of adjuvant treatment and for node positive ones who underwent adjuvant chemo or hormonotherapy. c-erbB-2 expression independently predicted poor survival among node negative tumors (p = 0.001) and was associated with ras expression among node positive cases (p = 0.04). If adjuvant treatment is included in the model, coexpressing tumors are less responsive to Tamoxifen and CMF regimens than those with low levels of protein expression (p = 0.04). These results are potentially of clinical value in separating a subset of node positive breast cancer patients for more intense postsurgical treatment. Among node negative patients, the sole expression of c-erbB-2 enhanced levels, is more likely to retain a predictive value in relation to the response after conventional adjuvant treatment.

Original languageEnglish
Pages (from-to)1441-1450
Number of pages10
JournalAnticancer Research
Volume14
Issue number3 B
Publication statusPublished - 1994

Fingerprint

Breast Neoplasms
Survival
ErbB-2 Receptor
ras Genes
Tamoxifen
Therapeutics
Disease-Free Survival
Neoplasms
Proteins
Multivariate Analysis
Western Blotting
Gene Expression
CMF regimen

Keywords

  • Adjuvant treatment
  • Breast cancer
  • c-erbB-2
  • Coexpression
  • ras expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Giai, M., Roagna, R., Ponzone, R., De Bortoli, M., Dati, C., & Sismondi, P. (1994). Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Research, 14(3 B), 1441-1450.

Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. / Giai, M.; Roagna, R.; Ponzone, R.; De Bortoli, M.; Dati, C.; Sismondi, P.

In: Anticancer Research, Vol. 14, No. 3 B, 1994, p. 1441-1450.

Research output: Contribution to journalArticle

Giai, M, Roagna, R, Ponzone, R, De Bortoli, M, Dati, C & Sismondi, P 1994, 'Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer', Anticancer Research, vol. 14, no. 3 B, pp. 1441-1450.
Giai, M. ; Roagna, R. ; Ponzone, R. ; De Bortoli, M. ; Dati, C. ; Sismondi, P. / Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. In: Anticancer Research. 1994 ; Vol. 14, No. 3 B. pp. 1441-1450.
@article{a3347cc1ad6d4472bb13fe029d691b05,
title = "Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer",
abstract = "The protein product of c-erbB-2 and ras oncogene has been examined for its prognostic potential in both node positive and node negative breast cancer. Using a western blot analysis, levels of these proteins were determined in 159 primary human breast tumor specimens. We examined relationships between gene expression and coexpression with other established markers of prognosis, as well as clinical outcome. Multivariate analysis showed that nodal involvement was the most powerful prognostic factor for predicting overall survival (<0.000) and disease-free survival (p = 0.001), whereas c-erbB-2 expression was second only to nodal status for predicting overall survival in the whole series (p = 0.05). A separated stepwise analysis was conducted for node negative patients who did not receive any kind of adjuvant treatment and for node positive ones who underwent adjuvant chemo or hormonotherapy. c-erbB-2 expression independently predicted poor survival among node negative tumors (p = 0.001) and was associated with ras expression among node positive cases (p = 0.04). If adjuvant treatment is included in the model, coexpressing tumors are less responsive to Tamoxifen and CMF regimens than those with low levels of protein expression (p = 0.04). These results are potentially of clinical value in separating a subset of node positive breast cancer patients for more intense postsurgical treatment. Among node negative patients, the sole expression of c-erbB-2 enhanced levels, is more likely to retain a predictive value in relation to the response after conventional adjuvant treatment.",
keywords = "Adjuvant treatment, Breast cancer, c-erbB-2, Coexpression, ras expression",
author = "M. Giai and R. Roagna and R. Ponzone and {De Bortoli}, M. and C. Dati and P. Sismondi",
year = "1994",
language = "English",
volume = "14",
pages = "1441--1450",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer

AU - Giai, M.

AU - Roagna, R.

AU - Ponzone, R.

AU - De Bortoli, M.

AU - Dati, C.

AU - Sismondi, P.

PY - 1994

Y1 - 1994

N2 - The protein product of c-erbB-2 and ras oncogene has been examined for its prognostic potential in both node positive and node negative breast cancer. Using a western blot analysis, levels of these proteins were determined in 159 primary human breast tumor specimens. We examined relationships between gene expression and coexpression with other established markers of prognosis, as well as clinical outcome. Multivariate analysis showed that nodal involvement was the most powerful prognostic factor for predicting overall survival (<0.000) and disease-free survival (p = 0.001), whereas c-erbB-2 expression was second only to nodal status for predicting overall survival in the whole series (p = 0.05). A separated stepwise analysis was conducted for node negative patients who did not receive any kind of adjuvant treatment and for node positive ones who underwent adjuvant chemo or hormonotherapy. c-erbB-2 expression independently predicted poor survival among node negative tumors (p = 0.001) and was associated with ras expression among node positive cases (p = 0.04). If adjuvant treatment is included in the model, coexpressing tumors are less responsive to Tamoxifen and CMF regimens than those with low levels of protein expression (p = 0.04). These results are potentially of clinical value in separating a subset of node positive breast cancer patients for more intense postsurgical treatment. Among node negative patients, the sole expression of c-erbB-2 enhanced levels, is more likely to retain a predictive value in relation to the response after conventional adjuvant treatment.

AB - The protein product of c-erbB-2 and ras oncogene has been examined for its prognostic potential in both node positive and node negative breast cancer. Using a western blot analysis, levels of these proteins were determined in 159 primary human breast tumor specimens. We examined relationships between gene expression and coexpression with other established markers of prognosis, as well as clinical outcome. Multivariate analysis showed that nodal involvement was the most powerful prognostic factor for predicting overall survival (<0.000) and disease-free survival (p = 0.001), whereas c-erbB-2 expression was second only to nodal status for predicting overall survival in the whole series (p = 0.05). A separated stepwise analysis was conducted for node negative patients who did not receive any kind of adjuvant treatment and for node positive ones who underwent adjuvant chemo or hormonotherapy. c-erbB-2 expression independently predicted poor survival among node negative tumors (p = 0.001) and was associated with ras expression among node positive cases (p = 0.04). If adjuvant treatment is included in the model, coexpressing tumors are less responsive to Tamoxifen and CMF regimens than those with low levels of protein expression (p = 0.04). These results are potentially of clinical value in separating a subset of node positive breast cancer patients for more intense postsurgical treatment. Among node negative patients, the sole expression of c-erbB-2 enhanced levels, is more likely to retain a predictive value in relation to the response after conventional adjuvant treatment.

KW - Adjuvant treatment

KW - Breast cancer

KW - c-erbB-2

KW - Coexpression

KW - ras expression

UR - http://www.scopus.com/inward/record.url?scp=0027993527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027993527&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1441

EP - 1450

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -